NASDAQ | ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology.
The fund is non-diversified.
Top 20 Holdings
Asset | Name | Sector | Industry | Weight |
---|---|---|---|---|
LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 5.10% |
RHHBY | Roche Holding Ltd ADR | Healthcare | Drug Manufacturers - General | 4.98% |
BBIO | BridgeBio Pharma Inc | Healthcare | Biotechnology | 4.93% |
RVMD | Revolution Medicines Inc | Healthcare | Biotechnology | 4.81% |
NOVN | Novartis AG | Healthcare | Drug Manufacturers - General | 4.23% |
EXEL | Exelixis Inc | Healthcare | Biotechnology | 4.04% |
AZN | AstraZeneca PLC | Healthcare | Drug Manufacturers - General | 4.01% |
MRUS | Merus BV | Healthcare | Biotechnology | 3.79% |
GMAB | Genmab AS | Healthcare | Biotechnology | 3.71% |
SMMT | Summit Therapeutics PLC | Healthcare | Biotechnology | 3.61% |
NUVL | Nuvalent Inc | Healthcare | Biotechnology | 3.57% |
BMY | Bristol-Myers Squibb Company | Healthcare | Drug Manufacturers - General | 3.38% |
AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 3.34% |
ACLX | Arcellx Inc | Healthcare | Biotechnology | 3.15% |
IMGN | ImmunoGen Inc | Healthcare | Biotechnology | 3.00% |
LEGN | Legend Biotech Corp | Healthcare | Biotechnology | 2.97% |
ZLAB | Zai Lab Ltd | Healthcare | Biotechnology | 2.94% |
BGNE | BeiGene Ltd | Healthcare | Biotechnology | 2.59% |
MRK | Merck & Company Inc | Healthcare | Drug Manufacturers - General | 2.56% |
IDYA | Ideaya Biosciences Inc | Healthcare | Biotechnology | 2.09% |